This study evaluates the optimal approach to treating cancer in older patients with other diseases that might put them at additional risk from cancer-directed treatments.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06138561.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer InstituteStatus: Active
Contact: Joaquim Bellmunt
Brigham and Women's HospitalStatus: Active
Contact: Joaquim Bellmunt
PRIMARY OBJECTIVE:
I. To evaluate the difference in NFBISI-18 scores as a quality of life measurement between patients treated with EV/pembrolizumab vs. carboplatin-based chemotherapy followed by immunotherapy maintenance (SM).
II. To evaluate the difference in patient reported adverse events relevant to patients with bladder cancer (via the NCI PRO-CTCAE questionnaire) between patients treated with EV-pembrolizumab vs. carboplatin-based chemotherapy followed by immunotherapy maintenance (SM).
OUTLINE: This is an observational study.
Patients complete questionnaires and have their medical records reviewed on study.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorJoaquim Bellmunt
